European CHMP Adopts Positive Opinion for Treatment of All Genotypes of Chronic Hepatitis C
Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.
The CHMP positive opinion was adopted following an accelerated review procedure, reserved for medicinal products expected to be of major public health interest. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union, Norway and Iceland.
You may be interested
Coronavirus Greece: 519 new cases, 321 intubated, 16 deathsPanos - Jun 18, 2021
Greece announced that the new laboratory-confirmed cases of coronavirus recorded in the last 24 hours are 519, of which 2…
Greece: Caroline was murdered by her husband!Panos - Jun 18, 2021
Charalambos Anagnostopoulos, the husband of 20-year-old Caroline Krauts, is according to the information available to the police her killer. The…
Covid measures: Playgrounds, amusement parks, therapeutic baths & massages to open – All the new datesPanos - Jun 18, 2021
The opening of outdoor playgrounds, amusement parks and therapeutic baths and massages from Saturday, June 19, is suggested by the…